newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - A